Effects of Acupuncture Combined with Yi Qi Yang Yin and Blood Activating Formula on Blood Glucose and Renal Function in Early Diabetic Nephropathy : A Randomized Controlled Trial
Objective: To study the effects of acupuncture combined with the formula of Yi Qi Yang Yin and blood activating (A-YBF) on blood glucose levels and renal function in patients with early diabetic nephropathy.
Methods: 96 patients with early diabetic nephropathy treated in our hospital from April 2021 to April 2022 were included in the study and divided into the control group (conventional medical treatment) and the study group (A-YBF), with 48 cases in each group. The efficacy and adverse effects were recorded by comparing the Chinese medicine symptom points, blood glucose level, renal function, and inflammatory factor level between the two groups before and after the treatment.
Results: The clinical efficacy of the study group was significantly higher than that of the control group (P < .05). Before treatment, no difference was found between the primary and secondary symptom scores of the two groups (P > .05); after treatment, the primary and secondary symptom scores of the study group were lower than those of the control group (P < .05). Before treatment, there was no difference in fasting blood glucose (FPG) and 2h postprandial glucose (2hPG) levels; 24h urine protein quantification, cystatin C (Cys-C), urinary albumin excretion rate (UAER), and estimated glomerular filtration rate (eGFR) levels; and growth differentiation factor-15 (GDF-15), interleukin-1β (IL-1β), interleukin-17 (IL-17), and serum amyloid A (SAA) levels between the two groups (P > .05). After treatment, FPG and 2hPG levels; 24h urine protein quantification, Cys-C and UAER levels; and GDF-15, IL-1β, IL-17, and SAA levels were lower in the study group than in the control group, while eGFR levels were higher than those in the control group (P < .05).
Conclusion: A-YBF can effectively reduce blood glucose levels and improve renal function in patients with early diabetic nephropathy and can be promoted in clinical application.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Alternative therapies in health and medicine - (2024) vom: 05. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Yange [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 06.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM370707222 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370707222 | ||
| 003 | DE-627 | ||
| 005 | 20240407232546.0 | ||
| 007 | tu | ||
| 008 | 240407s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1368.xml |
| 035 | |a (DE-627)NLM370707222 | ||
| 035 | |a (NLM)38581313 | ||
| 035 | |a (PII)AT8923 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Yange |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Acupuncture Combined with Yi Qi Yang Yin and Blood Activating Formula on Blood Glucose and Renal Function in Early Diabetic Nephropathy |b A Randomized Controlled Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 06.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Objective: To study the effects of acupuncture combined with the formula of Yi Qi Yang Yin and blood activating (A-YBF) on blood glucose levels and renal function in patients with early diabetic nephropathy | ||
| 520 | |a Methods: 96 patients with early diabetic nephropathy treated in our hospital from April 2021 to April 2022 were included in the study and divided into the control group (conventional medical treatment) and the study group (A-YBF), with 48 cases in each group. The efficacy and adverse effects were recorded by comparing the Chinese medicine symptom points, blood glucose level, renal function, and inflammatory factor level between the two groups before and after the treatment | ||
| 520 | |a Results: The clinical efficacy of the study group was significantly higher than that of the control group (P < .05). Before treatment, no difference was found between the primary and secondary symptom scores of the two groups (P > .05); after treatment, the primary and secondary symptom scores of the study group were lower than those of the control group (P < .05). Before treatment, there was no difference in fasting blood glucose (FPG) and 2h postprandial glucose (2hPG) levels; 24h urine protein quantification, cystatin C (Cys-C), urinary albumin excretion rate (UAER), and estimated glomerular filtration rate (eGFR) levels; and growth differentiation factor-15 (GDF-15), interleukin-1β (IL-1β), interleukin-17 (IL-17), and serum amyloid A (SAA) levels between the two groups (P > .05). After treatment, FPG and 2hPG levels; 24h urine protein quantification, Cys-C and UAER levels; and GDF-15, IL-1β, IL-17, and SAA levels were lower in the study group than in the control group, while eGFR levels were higher than those in the control group (P < .05) | ||
| 520 | |a Conclusion: A-YBF can effectively reduce blood glucose levels and improve renal function in patients with early diabetic nephropathy and can be promoted in clinical application | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Yang, Jiaxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Zhiyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Mengjin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alternative therapies in health and medicine |d 1998 |g (2024) vom: 05. Apr. |w (DE-627)NLM087670526 |x 1078-6791 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||